Pamlico BioPharma, Inc., an Oklahoma City-based research-stage biopharmaceutical company developing fully human monoclonal antibody (hmAb) therapeutics and point-of-care diagnostics, raised $2.2m in Series A equity financing.
The round was led by Accele Venture Partners, the investing arm of life sciences accelerator Accele Biopharma, and the Oklahoma Seed Capital Fund, managed by i2E, Inc.
The company intends to use the funds to advance research and development of human antibody therapeutics and diagnostics for infectious diseases and cancer.
Led by Clayton Duncan, Chairman and CEO, develops fully-human monoclonal antibody (hmAb) therapeutics for the rapid diagnosis and treatment of infectious diseases and cancer. The company isolated antibodies to all 24 vaccine serotypes of Streptococcus pneumoniae, influenza, varicella zoster, and rabies virus.
Its lead clinical candidate PneumomAb™ is a mixture of serotype-specific human monoclonal antibodies against Streptococcus pneumoniae (SPN). PneumomAb™ is in preclinical development for the treatment of severe community-acquired pneumococcal pneumonia (SPN-CAP).